InterVene
South San Francisco, CA · Healthcare · 50 employees
InterVene is a medical device start-up company reinventing the way physicians treat severe venous disease in the legs. InterVene's BlueLeaf(TM) Endovenous Valve Formation System represents the first ever non-implantable, endovenous approach to deep vein valve failure. This technology allows physicians to create new vein valves for patients who are unable to efficiently pump blood out of their legs
Funding history
- Series series a — $13.0M — Oct 2024
- Series seed — $1.5M — Mar 2023
- Series seed — $1.5M — Mar 2023
- Series seed — $2.2M — Jun 2017
Recent signals
- Oct 07, 2024: Raised $13.0M in Series series a
- Mar 07, 2023: Raised $1.5M in Series seed
- Mar 07, 2023: Raised $1.5M in Series seed
- Jun 07, 2017: Raised $2.2M in Series seed
See plans & pricing → Track InterVene’s funding, hiring, and signals — with verified contacts — on Fundz.